L-DOPA treatment selectively restores spine density in dopamine receptor D2–expressing projection neurons in dyskinetic mice
Background L-3, 4-dihydroxyphenylalanine (L-DOPA)–induced dyskinesia is an
incapacitating complication of L-DOPA therapy that affects most patients with Parkinson's
disease. Previous work indicating that molecular sensitization to dopamine receptor D 1
(D1R) stimulation is involved in dyskinesias prompted us to perform electrophysiological
recordings of striatal projection “medium spiny neurons”(MSN). Moreover, because
enhanced D1R signaling in drug abuse induces changes in spine density in striatum, we …
incapacitating complication of L-DOPA therapy that affects most patients with Parkinson's
disease. Previous work indicating that molecular sensitization to dopamine receptor D 1
(D1R) stimulation is involved in dyskinesias prompted us to perform electrophysiological
recordings of striatal projection “medium spiny neurons”(MSN). Moreover, because
enhanced D1R signaling in drug abuse induces changes in spine density in striatum, we …